ENDRA Life Sciences (NDRA) 10K Form and Latest SEC Filings 2026

ENDRA Life Sciences logo
$4.18 -0.24 (-5.45%)
Closing price 11/17/2026 03:59 PM Eastern
Extended Trading
$4.04 -0.14 (-3.35%)
As of 07:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest ENDRA Life Sciences SEC Filings & Recent Activity

ENDRA Life Sciences (NASDAQ:NDRA) has submitted 325+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 425 submitted on November 16, 2026.

8-K
ENDRA Life Sciences Files Current Report on Nov. 16, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
ENDRA Life Sciences Files Annual Report on Mar. 31, 2026

The 10-K contains ENDRA Life Sciences's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

ENDRA Life Sciences SEC Filing History

Browse ENDRA Life Sciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

Filing Date
0 Results
DateFilerForm TypeView
11/16/2026 4:04 PM
ENDRA Life Sciences (1681682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/16/2026 4:06 PM
ENDRA Life Sciences (1681682) Subject
Form 425
11/10/2026 6:54 AM
ENDRA Life Sciences (1681682) Subject
Salt Rock Capital Partners LLP (2163773) Filed by
Form SCHEDULE 13G
10/26/2026 3:16 PM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form 425
10/08/2026 3:15 PM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form SCHEDULE 13D
10/08/2026 3:15 PM
ASP Isotopes Inc. (1921865) Reporting
ENDRA Life Sciences (1681682) Issuer
LHE LNG Holdings LLC (2157843) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/01/2026 4:18 PM
ENDRA Life Sciences (1681682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/01/2026 4:21 PM
ENDRA Life Sciences (1681682) Subject
Form 425
09/25/2026 4:09 PM
ENDRA Life Sciences (1681682) Subject
Form 425
09/14/2026 4:15 PM
ENDRA Life Sciences (1681682) Subject
Form 425
09/09/2026 5:30 AM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form 425
09/09/2026 5:33 AM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form 425
08/20/2026 7:22 PM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form 425
08/20/2026 7:10 AM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form 425
08/17/2026 3:05 PM
ENDRA Life Sciences (1681682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/17/2026 3:07 PM
ENDRA Life Sciences (1681682) Subject
Form 425
08/06/2026 7:15 AM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form 425
08/05/2026 4:07 PM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form 425
08/04/2026 4:25 PM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form 425
07/22/2026 7:35 AM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form 425
07/22/2026 5:01 AM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form 425
07/17/2026 7:20 AM
ENDRA Life Sciences (1681682) Subject
Form 425
07/17/2026 7:20 AM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form 425
07/09/2026 5:08 AM
ENDRA Life Sciences (1681682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/29/2026 8:29 PM
DIGIANDOMENICO ANTHONY (1083544) Filed by
ENDRA Life Sciences (1681682) Subject
Form SCHEDULE 13D/A
06/26/2026 5:10 AM
ENDRA Life Sciences (1681682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/26/2026 5:16 AM
ENDRA Life Sciences (1681682) Subject
Form 425
06/25/2026 5:24 PM
DIGIANDOMENICO ANTHONY (1083544) Reporting
ENDRA Life Sciences (1681682) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/25/2026 4:25 PM
ASP Isotopes Inc. (1921865) Filed by
ENDRA Life Sciences (1681682) Subject
Form 425
06/25/2026 8:38 AM
ENDRA Life Sciences (1681682) Subject
Form 425
06/25/2026 8:37 AM
ENDRA Life Sciences (1681682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/28/2026 5:07 AM
ENDRA Life Sciences (1681682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/26/2026 3:59 PM
ENDRA Life Sciences (1681682) Filer
Form RW
04/21/2026 7:00 AM
ENDRA Life Sciences (1681682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/31/2026 4:10 PM
ENDRA Life Sciences (1681682) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/25/2026 8:21 AM
ENDRA Life Sciences (1681682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/04/2026 8:48 PM
ENDRA Life Sciences (1681682) Issuer
Jacroux Richard (2033818) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 8:48 PM
ENDRA Life Sciences (1681682) Issuer
Tokman Alexander Y (1334483) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2026 6:42 PM
ENDRA Life Sciences (1681682) Issuer
Tokman Alexander Y (1334483) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2026 6:43 PM
Basenese Lou (1809482) Reporting
ENDRA Life Sciences (1681682) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2026 6:43 PM
ENDRA Life Sciences (1681682) Issuer
Jacroux Richard (2033818) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
Why I'm selling my Snapback Indicator for just $7 (Ad)

For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel

Get lifetime access to the Snapback Indicator for a one-time $7 payment today.
01/23/2026 6:43 PM
ENDRA Life Sciences (1681682) Issuer
Harsh Michael (1706155) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2026 6:44 PM
DIGIANDOMENICO ANTHONY (1083544) Reporting
ENDRA Life Sciences (1681682) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2025 7:31 PM
ENDRA Life Sciences (1681682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/28/2025 3:23 PM
ENDRA Life Sciences (1681682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/26/2025 3:30 PM
DIGIANDOMENICO ANTHONY (1083544) Filed by
ENDRA Life Sciences (1681682) Subject
Form SCHEDULE 13D
11/26/2025 7:30 AM
ENDRA Life Sciences (1681682) Filer
Form 424B4
(Data available from 1/1/2016 forward)

ENDRA Life Sciences SEC Filings - Frequently Asked Questions

ENDRA Life Sciences (NDRA) has submitted 325+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

ENDRA Life Sciences's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 425 submitted on November 16, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:NDRA are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 11/16/2026. New filings are added as they're published.
From Our Partners